🔧 Resistant HTN & Device Therapy

2025 AHA/ACC Renal Denervation and Advanced Management

Visual reference

Resistant Hypertension: Verify, Investigate, Then Escalate visual summary. Open for the full image and text version.
Resistant Hypertension: Verify, Investigate, Then Escalate: full graphic and text version

Browse the visual reference library · Download lesson Markdown

🚀 Breakthrough 2025 Integration

Renal denervation receives formal Class 2b recommendation marking the first device-based therapy integration in AHA/ACC hypertension guidelines. This represents a paradigm shift toward interventional management of resistant hypertension.

🔍 Resistant Hypertension: Systematic Evaluation

📋 Definition: Resistant Hypertension

Blood pressure remains above goal despite 3 optimally-dosed antihypertensives from different classes, including a diuretic, OR controlled on ≥4 medications

1

Confirm True Resistance

Out-of-office BP monitoring: ABPM or HBPM to exclude white-coat effect

Medication review: Verify optimal dosing, appropriate combinations, patient adherence

2

Assess Adherence

Pharmacy records: Prescription filling patterns, timing analysis

Drug levels: When available, direct measurement of medication concentrations

3

Screen for Secondary Causes

Primary aldosteronism: Universal screening with ARR (Class 1 recommendation)

Other causes: Sleep apnea, renal artery stenosis, pheochromocytoma evaluation

4

Optimize Medical Therapy

Fourth-line agent: Spironolactone 12.5-50 mg daily (Class 1 recommendation)

Alternative agents: Amiloride, eplerenone, or other evidence-based combinations

5

Consider Device Therapy

Renal denervation: Class 2b recommendation for selected patients

Multidisciplinary evaluation: Required before procedural intervention

💊 Advanced Treatment Strategies

🧪 Spironolactone: Fourth-Line Therapy Class 1

📊 Efficacy in Resistant HTN (PATHWAY-2)
  • BP Reduction: −8.7 mmHg home systolic vs placebo (95% CI −9.7 to −7.7)
  • Best-of-four ranking: Spironolactone most effective of 4 add-on drugs in approximately 58% of patients in crossover
  • Optimal Dose: 12.5-50 mg daily (titrate based on response/tolerance)
  • Source: Williams B et al. Lancet 2015;386(10008):2059-2068. PMID 26414968
✅ Ideal Candidates:
  • eGFR ≥45 mL/min/1.73m²
  • Potassium <4.5 mEq/L
  • No significant kidney disease
  • Volume-dependent resistant HTN
⚠️ Monitoring Protocol:

Check electrolytes and creatinine at 1 week, 1 month, then quarterly. Watch for hyperkalemia (>5.5 mEq/L) and acute kidney injury.

🔧 Renal Denervation Class 2b

📈 Contemporary Evidence
  • Office BP: 5-10 mmHg systolic reduction
  • 24-hour ABPM: 3-8 mmHg reduction
  • Response Rate: 60-70% show clinically meaningful reduction
  • Durability: Effects maintained at 3 years
🎯 Patient Selection Criteria:
  • Office SBP 140-180 mmHg despite treatment
  • Documented medication adherence
  • eGFR ≥40 mL/min/1.73m²
  • Suitable renal artery anatomy
  • Life expectancy >1 year
❌ Contraindications:
  • Significant renovascular abnormalities
  • Previous renal artery intervention
  • Type 1 diabetes with neuropathy
  • eGFR <40 mL/min/1.73m²

⚗️ Alternative Combination Strategies

🔄 When Spironolactone Intolerant:
  • Amiloride: 5-10 mg daily (K+-sparing, less hormonal effects)
  • Eplerenone: 25-100 mg daily (selective MR antagonist)
  • Beta-blockers: Carvedilol, bisoprolol if not contraindicated
  • Alpha-blockers: Doxazosin XL for volume-independent resistance
🧬 Novel Agents (Research):
  • Finerenone: Non-steroidal MR antagonist
  • SGLT2 inhibitors: Modest BP effects + cardiorenal protection
  • GLP-1 agonists: 3-5 mmHg reduction + weight loss

🔬 Renal Denervation: Comprehensive Overview

🔬 Mechanism of Action

  • Sympathetic nerve ablation: Disrupts renal afferent/efferent pathways
  • Central effects: Reduces overall sympathetic tone
  • Local renal effects: Decreases renin release, sodium retention
  • Vascular effects: Improved endothelial function

⚕️ Procedure Details

  • Approach: Percutaneous, femoral artery access
  • Technology: Radiofrequency or ultrasound ablation
  • Duration: 45-90 minutes outpatient procedure
  • Recovery: Same-day discharge, minimal downtime

📊 Key Clinical Trial Data

SPYRAL HTN-OFF MED Pivotal

24-h ABPM: -3.9 mmHg SBP vs sham (95% CrI -6.2 to -1.6)
Office SBP: -6.5 mmHg vs sham
Bohm 2020 Lancet, PMID 32234534

SPYRAL HTN-ON MED

24-h ABPM: -7.4 mmHg SBP vs sham (95% CI -12.5 to -2.3)
Office SBP: -6.8 mmHg vs sham
Kandzari 2018 Lancet, PMID 29803589

RADIANCE-HTN SOLO

Daytime ABPM: -6.3 mmHg baseline-adjusted SBP difference (95% CI -9.4 to -3.1)
Office SBP: approximately -6.5 mmHg between-group
Azizi 2018 Lancet, PMID 29803590

👥 Multidisciplinary Team Evaluation (Class 1 Requirement)

🩺 Hypertension Specialist

  • Confirm true resistance
  • Optimize medical therapy
  • Exclude secondary causes
  • Long-term BP management

🫀 Interventional Cardiologist

  • Assess procedural feasibility
  • Evaluate renal artery anatomy
  • Perform procedure if appropriate
  • Manage complications

🧠 Clinical Psychologist

  • Assess adherence barriers
  • Evaluate decision-making capacity
  • Support lifestyle modifications
  • Manage treatment expectations

💊 Clinical Pharmacist

  • Medication reconciliation
  • Drug interaction screening
  • Adherence optimization
  • Cost-effective alternatives

🤝 Shared Decision-Making Considerations

✅ Potential Benefits
  • Modest but clinically meaningful BP reduction
  • Potential medication reduction
  • No systemic drug effects
  • Durable effects at 3+ years
  • Improved quality of life scores
⚠️ Limitations & Risks
  • 30-40% non-response rate
  • Continued medication requirement
  • Procedural costs and access
  • Potential need for repeat procedures
  • Limited long-term outcome data

📊 Treatment Evidence Summary

Treatment Class/Level BP Reduction Response Rate Key Considerations
Spironolactone Class 1 −8.7 mmHg home SBP vs placebo (PATHWAY-2) Best-of-4 in approximately 58% (crossover) Monitor K+, creatinine; eGFR ≥45 required
Amiloride Class 2a 10-15 mmHg 50-60% Alternative if spironolactone intolerant
Renal Denervation Class 2b 5-10 mmHg 60-70% Multidisciplinary evaluation required
Beta-blockers Class 2b 8-12 mmHg 40-50% Carvedilol preferred; avoid if contraindicated
Alpha-blockers Class 2b 6-10 mmHg 40-50% Doxazosin XL; monitor orthostatic hypotension

📚 Sources

  1. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2). Lancet. 2015;386(10008):2059-2068. PMID: 26414968.
  2. Bhatt DL, Kandzari DE, O'Neill WW, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. PMID: 24678939.
  3. Böhm M, Kario K, Kandzari DE, et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications. Lancet. 2020;395(10234):1444-1451. PMID: 32234534.
  4. Kandzari DE, Böhm M, Mahfoud F, et al; SPYRAL HTN-ON MED. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs. Lancet. 2018;391(10137):2346-2355. PMID: 29803589.
  5. Azizi M, Schmieder RE, Mahfoud F, et al; RADIANCE-HTN SOLO. Endovascular ultrasound renal denervation to treat hypertension. Lancet. 2018;391(10137):2335-2345. PMID: 29803590.
  6. Carey RM, Calhoun DA, Bakris GL, et al; American Heart Association. Resistant Hypertension: Detection, Evaluation, and Management. Hypertension. 2018;72(5):e53-e90. PMID: 30354828.
  7. Brown C, Clark D, Jones DW. Updates in the 2025 AHA/ACC Hypertension Guideline. Curr Hypertens Rep. 2026;28(1). PMID: 41843050. [Source for: 2025 update — RDN as adjunctive option in select resistant-HTN patients.]

🎯 Resistant HTN & Device Therapy: Key Learning Points

🔍 Systematic Evaluation

  • Confirm resistance with out-of-office monitoring
  • Assess adherence through pharmacy records
  • Universal primary aldosteronism screening
  • Optimize medical therapy before devices

💊 Medical Optimization

  • Spironolactone is Class 1 fourth-line therapy
  • −8.7 mmHg additional home SBP vs placebo (PATHWAY-2, PMID 26414968) — set patient expectations accordingly
  • Monitor electrolytes and renal function
  • Alternative agents for intolerance

🔧 Device Therapy

  • Renal denervation: modest but durable effects
  • Multidisciplinary evaluation mandatory
  • 30-40% non-response rate expected
  • Continued medications still required

📚 For Educational Purposes Only

© 2025 University of Dubuque PA Program - All Rights Reserved